Back to Search
Start Over
Triglyceride-mediated pathways and coronary disease: collaborative analysis of 101 studies
- Source :
- The Lancet, 375(9726), 1634-1639, ResearcherID, Lancet, Lancet, 375(9726), 1634-1639. Elsevier Limited, Sarwar, N, Butterworth, A S, Di Angelantonio, E, Ouwehand, W, Watkins, H, Lawlor, D, Hingorani, A D, Braund, P S, Hall, A S, Samani, N J, Thompson, J, Marz, W, Sivapalaratnam, S, Soranzo, N, Trip, M, Lawlor, D A, Casas, J P, Arsenault, B J, Boekholdt, S M, Khaw, K T, Ricketts, S L, Sandhu, M S, Wareham, N J, Grallert, H, Illig, T, Humphries, S E, Talmud, P J, Rader, D J, He, J, Reilly, M P, Clarke, R, Hamsten, R, Hopewell, J C, Saleheen, D, Frossard, P, Deloukas, P, Danesh, J, Ye, S, Simpson, J A, Onat, A, Komurcu-Bayrak, E, Martinelli, N, Olivieri, O, Girelli, D, Kivimaki, M, Kumari, M, Aouizerat, B E, Baum, L, Campos, H, Chaaba, R, Chen, B S, Cho, E Y, Evans, D, Hill, J, Hsu, L A, Hubacek, J A, Lai, C Q, van der Lee, J H, Klos, K, Liu, H, Masana, L, Melegh, B, Nabika, T, Ribalta, J, Ruiz-Narvaez, E, Thomas, G N, Tomlinson, B, Szalai, C, Vaverkova, H, Yamada, Y, Yang, Y, Tipping, R W, Ford, C E, Pressel, S L, Ballantyne, C, Brautbar, A, Knuiman, M, Winchup, P H, Wannamethee, S G, Morris, R W, Kiechl, S, Willeit, J, Santer, P, Mayr, A, Wald, N, Dekker, J M, Nijpels, G, White, I R & Wood, A M 2010, ' Triglyceride-mediated pathways and coronary disease: collaborative analysis of 101 studies ', Lancet, vol. 375, no. 9726, pp. 1634-1639 . https://doi.org/10.1016/S0140-6736(10)60545-4, Lancet, 375(9726), 1634-1639. Elsevier Science, Sarwar, N, Sandhu, M S, Ricketts, S L, Butterworth, A S, Di Angelantonio, E, Boekholdt, S M, Ouwehand, W, Watkins, H, Samani, N J, Saleheen, D, Lawlor, D, Reilly, M P, Hingorani, A D, Talmud, P J, Danesh, J, Bladbjerg, E-M, Jespersen, J & Ukendt, M F 2010, ' Triglyceride-mediated pathways and coronary disease : collaborative analysis of 101 studies ', Lancet, vol. 375, no. 9726, pp. 1634-9 . https://doi.org/10.1016/S0140-6736(10)60545-4, University of Helsinki, Lancet, 375(9726), 1634-1639, The Lancet 375 (2010) 9726
- Publisher :
- Elsevier Ltd.
-
Abstract
- Udgivelsesdato: May-8 BACKGROUND: Whether triglyceride-mediated pathways are causally relevant to coronary heart disease is uncertain. We studied a genetic variant that regulates triglyceride concentration to help judge likelihood of causality. METHODS: We assessed the -1131T>C (rs662799) promoter polymorphism of the apolipoprotein A5 (APOA5) gene in relation to triglyceride concentration, several other risk factors, and risk of coronary heart disease. We compared disease risk for genetically-raised triglyceride concentration (20,842 patients with coronary heart disease, 35,206 controls) with that recorded for equivalent differences in circulating triglyceride concentration in prospective studies (302 430 participants with no history of cardiovascular disease; 12,785 incident cases of coronary heart disease during 2.79 million person-years at risk). We analysed -1131T>C in 1795 people without a history of cardiovascular disease who had information about lipoprotein concentration and diameter obtained by nuclear magnetic resonance spectroscopy. FINDINGS: The minor allele frequency of -1131T>C was 8% (95% CI 7-9). -1131T>C was not significantly associated with several non-lipid risk factors or LDL cholesterol, and it was modestly associated with lower HDL cholesterol (mean difference per C allele 3.5% [95% CI 2.6-4.6]; 0.053 mmol/L [0.039-0.068]), lower apolipoprotein AI (1.3% [0.3-2.3]; 0.023 g/L [0.005-0.041]), and higher apolipoprotein B (3.2% [1.3-5.1]; 0.027 g/L [0.011-0.043]). By contrast, for every C allele inherited, mean triglyceride concentration was 16.0% (95% CI 12.9-18.7), or 0.25 mmol/L (0.20-0.29), higher (p=4.4x10(-24)). The odds ratio for coronary heart disease was 1.18 (95% CI 1.11-1.26; p=2.6x10(-7)) per C allele, which was concordant with the hazard ratio of 1.10 (95% CI 1.08-1.12) per 16% higher triglyceride concentration recorded in prospective studies. -1131T>C was significantly associated with higher VLDL particle concentration (mean difference per C allele 12.2 nmol/L [95% CI 7.7-16.7]; p=9.3x10(-8)) and smaller HDL particle size (0.14 nm [0.08-0.20]; p=7.0x10(-5)), factors that could mediate the effects of triglyceride. INTERPRETATION: These data are consistent with a causal association between triglyceride-mediated pathways and coronary heart disease. FUNDING: British Heart Foundation, UK Medical Research Council, Novartis.
- Subjects :
- Very low-density lipoprotein
Nutrition and Disease
Heart disease
Coronary Disease
Lipoproteins, VLDL
030204 cardiovascular system & hematology
low-density-lipoprotein apolipoprotein-a-v transfer protein heart-disease myocardial-infarction metabolic syndrome rich lipoproteins risk dyslipidemia association
Bioinformatics
chemistry.chemical_compound
0302 clinical medicine
triglyceride
APOA5 gene polymorphysm
coronary heart disease
Gene Frequency
Risk Factors
Voeding en Ziekte
Medicine
Myocardial infarction
Promoter Regions, Genetic
risk
0303 health sciences
Men
Mendelian Randomization Analysis
Articles
General Medicine
Lipids
myocardial-infarction
3. Good health
Lipoproteins, LDL
Low-density lipoprotein
Lipoproteins, HDL
apolipoprotein-a-v
Receptor
medicine.medical_specialty
Genotype
transfer protein
Snp
Polymorphism, Single Nucleotide
metabolic syndrome
03 medical and health sciences
Internal medicine
Humans
Particle Size
Apolipoproteins A
Triglycerides
VLAG
030304 developmental biology
low-density-lipoprotein
Triglyceride
business.industry
dyslipidemia
association
rich lipoproteins
medicine.disease
heart-disease
Apolipoproteins
Endocrinology
chemistry
Apolipoprotein A-V
Metabolic syndrome
business
Dyslipidemia
Subjects
Details
- Language :
- English
- ISSN :
- 01406736
- Issue :
- 9726
- Database :
- OpenAIRE
- Journal :
- The Lancet
- Accession number :
- edsair.doi.dedup.....879adec53b90ddddc984e52344a87eda
- Full Text :
- https://doi.org/10.1016/S0140-6736(10)60545-4